Thrombozytenaggregationshemmer

H. Patscheke

doi:10.1055/s-0037-1619595

Hämostaseologie, Table of Contents

Hamostaseologie 2003; 23(04): 181-185
DOI: 10.1055/s-0037-1619595

Original Article

Schattauer GmbH

Thrombozytenaggregationshemmer

Inhibitors of platelet aggregation

H. Patscheke

¹Zentrum für Labormedizin, Mikrobiologie und Transfusionsmedizin, Städtisches Klinikum Karlsruhe

› Author Affiliations

Abstract

Zusammenfassung

Unabhängig von ihrem Wirkungsmechanismus greifen Antikoagulanzien stets unmittelbar in die Bildung und Wirkung von Thrombin und damit die Endstrecke der Gerinnung ein. Von den Aggregationshemmern hemmen nur die GPIIb/IIIa-Antagonisten die gemeinsame Endstrecke der Plättchenaggregation, indem sie die Bildung von Fibrinogen/von-Willebrand-Faktor-vermittelten Plättchen-Plättchen-Brücken hemmen.

Azetylsalizylsäure (ASS), NSARs, Clopidogrel oder Ticlopidin begrenzen die Plättchenaktivierung dagegen, indem sie die Bildung bzw. Wirkung der sekundären Plättchenagonisten Thromboxan A₂ bzw. ADP ausschalten, aber z. B. die durch Thrombin direkt induzierbare Plättchenaggregation nicht. Deshalb rufen ASS, Clopidogrel oder Ticlopidin allein kein wesentliches Blutungsrisiko hevor, wenn nicht weitere, die Hämostase beeinträchtigende Faktoren (z.B. ausgeprägte Thrombozytopenie, Antikoagulation) vorliegen. Deshalb entfällt für diese Hemmstoffe auch die Notwendigkeit der Therapiekontrolle. Beim therapeutischen Einsatz von ASS als Aggregationshemmer ist vielmehr die Dosierung darauf abzustellen, eine vollständige Blockade (mind. 90%) der Thromboxanbiosynthese in den Plättchen zu erreichen, um überhaupt einen therapeutischen bzw. prophylaktischen Effekt zu erzielen.

Von den GPIIb/IIIa-Antagonisten sind nur die parenteral eingesetzten (Abciximab, Eptifibatid, Tirofiban) zugelassen. Orale GPIIb/IIIa-Antagonisten zeigten bisher in klinischen Studien ein erhöhtes Blutungsrisiko bei nicht ausreichendem therapeutischen Nutzen. Die meisten GPIIb/IIIa-Antagonisten verursachen eine leichte Thrombozytopenie, als deren Auslöser die Inhibitor-Rezeptor-Wechselwirkung bzw. immunologische Mechanismen diskutiert werden. Für das spezifische Monitoring dieser potenten Aggregationshemmer ist ein »Point-of-Care«-Testsystem verfügbar. Für die Einschätzung des Blutungsrisikos müssen jedoch stets alle, die Hämostase beeinflussende Faktoren berücksichtigt werden. Das gilt insbesondere, wenn neben GPIIb/IIIa-Antagonisten Heparin u.a. Wirkstoffe eingesetzt werden.

Summary

Irrespective of their mechanism of action, anticoagulants reduce the formation and action of thrombin. Thus they interfere with a final step in coagulation. Among platelet inhibitors only the GPIIb/IIIa antagonists inhibit the common pathway of aggregation, namely the formation of platelet-to-platelet bridges which are mediated by fibrinogen or von Willebrand factor.

In contrast, acetylsalicylic acid (ASA), NSAIDs, clopidogrel (Plavix^®) or ticlopidine (Tyklid^®) inhibit platelet activation by abrogating the formation or action of a secondary platelet agonist, namely of thromboxane A₂ or ADP. They do not block platelet aggregation which is directly induced by thrombin. Therefore, ASA, clopidogrel, or ticlopidine are not associated with a significant risk of bleeding as long as other factors such as an extensive thrombocytopenia or anticoagulation are not involved. Therefore, in contrast to anticoagulants, therapeutic drug monitoring is not necessary with ASA, clopidogrel, nor ticlopidine. On the other hand, ASA has even to be applied at a dosage that almost completely inhibits thromboxane synthesis in order to act on platelet aggregation at all.

Among the GPIIb/IIIa-antagonists only parenteral drugs have been approved for therapeutic use, e. g. abciximab (ReoPro^®), eptifibatide (Integrilin^®), and tirofiban (Aggrastat^®). Clinical studies revealed an increased risk of bleeding without a sufficient therapeutic benefit of oral GPIIb/IIIa antagonists. GPIIb/IIIa antagonists may induce thrombocytopenia that is attributed to an outside-in signalling or immunological phenomena. A test system (Ultegra, Accumetrics) is available for a therapeutic drug monitoring of GPIIb/IIIa antagonists. However, estimation of the bleeding risk always requires an evaluation of all factors influencing the haemostatic system, especially when heparin or other inhibitors are applied additionally.

Schlüsselwörter

GPIIb/IIIa-Antagonisten - Azetylsalizylsäure - Clopidogrel - Ticlopidin - Thrombozytenaggregation

Keywords

GPIIb/IIIa antagonists - acetylsalicylic acid - clopidogrel - ticlopidine - platelet aggregation

Full Text

References

Literatur
1 Akkerhuis KM, Neuhaus KL, Wilcox RG. et al. Fibrinogen Receptor Occupancy Study (FROST) Investigators. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study. Eur Heart J 2000; 21: 2042-55.
2 Anderluh M, Dolene MS. Thrombin receptor antagonists; recent advances in PAR-1 antagonist development. Curr Med Chem 2002; 9: 1229-50.
3 Batchelor WB, Tolleson TR, Huang Y. et al. Randomized comparison of platelet inhibition with abciximab, tirofiban and eptifibratide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation 2002; 106: 1470-6.
4 Bennett CL, Cavidson CJ, Raisch DW. et al. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999; 159: 2524-8.
5 Bennett CL, Connors JM, Carwile JM. et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342: 1773-7.
6 Berger PB, Mahaffey KW, Meier SJ. et al. The ATLAST Investigators. Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. Am Heart J 2002; 143: 841-6.
7 Bode-Boger SM, Boger RH, Schubert M. et al. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects. Eur J Clin Pharmacol 1998; 54: 707-14.
8 Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996; 76: 939-43.
9 Braunwald E, Antman EM, Beasley JW. et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002; 106: 1893-900.
10 Buchanan MR, Schwartz L, Bourassa M. et al. Results of the BRAT study – a pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol 2000; 16: 1385-90.
11 Budaj A, Yusuf S, Mehta SR. et al. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 2002; 106: 1622-6.
12 CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
13 Cannon CP, McCabe CH, Wilcox RG. et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000; 102: 149-56.
14 Chung AW, Jurasz P, Hollenberg MD. et al. Mechanisms of action of proteinase-activated receptor agonists on human platelets. Br J Pharmacol 2002; 135: 1123-32.
15 Gachet C. Identification, characterization, and inhibition of the platelet ADP receptors. Int J Hematol 2001; 74: 375-81.
16 Gawaz M, Ruf A, Pogatsa-Murray G. et al. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors. Thromb Haemost 2000; 83: 915-22.
17 Jennings LK, Jacoski MV, White MM. The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors. J Interv Cardiol 2002; 15: 45-60.
18 Kalinowski L, Matys T, Chabielska E. et al. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002; 40: 521-7.
19 Kamishirado H, Inoue T, Mizoguchi K. et al. Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. Am Heart J 2002; 144: 303-8.
20 Kondo K, Umenura K. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab. Clin Pharmacokinet 2002; 41: 187-95.
21 Lubbe DF, Berger PB. The thienopyridines. J Interv Cardiol 2002; 15: 85-93.
22 Medina PJ, Sipols Jm, George JN. Drug-associated thrombotic thrombocytopenic purpurahemolytic uremic syndrome. Curr Opin Hematol 2001; 8: 286-93.
23 O’Connor FF, Shields DC, Fitzgerald A. et al. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 2001; 98: 3256-60.
24 Pereillo JM, Maftouh M, Andrieu A. et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002; 30: 1288-95.
25 Peter K, Schwarz M, Nordt T. et al. Intrinsic activating properties of GP IIb/IIIa blockers. Thromb Res 2001; 103 (Suppl. 01) S21-7.
26 Peters AJ, Borries M, Gradaus F. et al. In vitro bleeding test with PFA-100 – aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease. Thromb Thrombol 2001; 12: 263-72.
27 Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999; 100: 1667-72.
28 Schomig A, Neumann FJ, Kastrati A. et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-9.
29 Sun B, Le SN, Lin S. et al. New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation. J Cardiovasc Pharmacol 2002; 40: 577-85.
30 The SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet 2000; 355: 337-45.
31 Thompson CM, Steinhubl SR. Monitoring of platelet function in the setting of glycoprotein IIb/IIIa inhibitor therapy. J Interv Cardiol 2002; 15: 61-70.
32 Tsai HM, Rice L, Sarode R, Chow TW, Moake JL. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000; 132: 794-9.